Shopping Cart
- Remove All
- Your shopping cart is currently empty
iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1.
Pack Size | Price | Availability | Quantity |
---|---|---|---|
10 mg | Inquiry | 10-14 weeks | |
50 mg | Inquiry | 10-14 weeks |
Description | iBFAR2, an inhibitor of BFAR, restores the CD8+ tumor-resident memory T cell subset against solid tumors. It promotes the binding of JAK2-STAT1 and enhances the phosphorylation of STAT1. |
In vitro | iBFAR2 eliminated USP39 ubiquitination in primary mouse CD8+ T cells, inhibited the interaction between JAK2 and USP39, and thereby prevented the deubiquitination of JAK2. This, in turn, facilitated the binding of JAK2 and STAT1, enhancing the phosphorylation of STAT1. |
In vivo | The compound iBFAR2 (ip; 1, 5, 10 mg/kg; administered once every 2 days starting from day 7 with 9 mice per group) inhibits the growth of MB49 tumors in a dose-dependent manner. |
Molecular Weight | 360.33 |
Formula | C19H15F3N2O2 |
Cas No. | 353484-02-3 |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice./Shipping at ambient temperature. |
Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.